RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Drfreely, Don't forget the 4th 'D' -- 'Drug Does Work'.


Ampakines do in fact work in RD and Central SA (as well as ADHD). While that didn't lead to a big pharma deal (other than the $10 mil Biovail deal, negated by their Valeant merger), it looks like Cortex will now get another chance, this time with the superior CX-1739.

Compared to CX-717, CX-1739 is artifact-free, has patent life to 2028, and is more potent. And there will be the injectable Ampakine CX-1942, which is ideal for RD rescue from opioid or Propofol overdose. Combined with the SA Phase 2a data
for CX-1739 (Central and Mixed SA), Cortex will have a nice package of data for partnering.

Anyway, hope (and wishful thinking) springs eternal :o)